Novel agents in myeloma: an exciting saga.

about

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes.

P2860

Q34635516-DC23CEE2-F221-411E-BBC1-66D74E086C21 Q35580212-F2308DE2-6372-471D-B1E5-4F55C7DE7F0A

P2860

Novel agents in myeloma: an exciting saga.

Item

http://www.wikidata.org/entity/Q46233627

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Novel agents in myeloma: an exciting saga.

@en

Novel agents in myeloma: an exciting saga.

@nl

type

Item

label

Novel agents in myeloma: an exciting saga.

@en

Novel agents in myeloma: an exciting saga.

@nl

prefLabel

Novel agents in myeloma: an exciting saga.

@en

Novel agents in myeloma: an exciting saga.

@nl

P1476

Novel agents in myeloma: an exciting saga.

@en

P2093

Morton Coleman

http://www.w3.org/2001/XMLSchema#string

Tomer Mark

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.

Antitumor activity of thalidomide in refractory multiple myeloma.

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

IMiDs: a novel class of immunomodulators.

NF-kappa B as a therapeutic target in multiple myeloma.

P304

236-242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24040

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Ruben Niesvizky

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23489932

http://www.w3.org/2001/XMLSchema#string

P698

19025986

http://www.w3.org/2001/XMLSchema#string

Novel agents in myeloma: an exciting saga.

about

P2860

P2860

Novel agents in myeloma: an exciting saga.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698